Business
Hemogenyx Pharmaceuticals PLC Announces First Patient Safety
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF ...
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.","length":370,"tagName":"p"},{"type":"text","content":"24 March 2025","length":13,"tagName":"p"},{"type":"text","content":"Hemogenyx Pharmaceuticals plc","length":29,"tagName":"p"},{"type":"text","content":"("Hemogenyx Pharmaceuticals" or the "Company")","length":66,"tagName":"p"},{"type":"text","content":"First Patient Treated with HG-CT-1 CAR-T Therapy Passes Initial Safety Tests","length":76,"tagName":"p"},{"type":"text","content":"LONDON, UNITED KINGDOM / ACCESS Newswire / March 24, 2025 / Hemogenyx Pharmaceuticals plc is pleased to announce that the first patient has been successfully treated as part of the Company's Phase I clinical trial of HG-CT-1, the Company's proprietary CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (R/R AML) in adults. The treatment was well tolerated, with no adverse effects observed, thereby passing the initial safety assessment.","length":464,"tagName":"p"},{"type":"text","content":"Early signs of efficacy are encouraging. The patient will continue to be monitored in accordance with the FDA-approved clinical protocol to evaluate whether the secondary endpoints of the trial are achieved.","length":207,"tagName":"p"},{"type":"text","content":"Manufacturing of HG-CT-1 is currently underway for the treatment of a second patient.","length":85,"tagName":"p"},{"type":"text","content":"This Phase I clinical trial is a dose-escalation study designed to evaluate the safety profile of HG-CT-1 in adult patients with R/R AML. In addition to safety, key secondary objectives of the trial include:","length":207,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Assessing the efficacy of HG-CT-1 based on AML-specific response criteria","length":73,"tagName":"p"}]},{"val":[{"type":"text","content":"Evaluating overall survival","length":27,"tagName":"p"}]},{"val":[{"type":"text","content":"Measuring progression-free survival","length":35,"tagName":"p"}]},{"val":[{"type":"text","co...